CRISPR Therapeutics AG $CRSP Stake Decreased by Brave Asset Management Inc.

Brave Asset Management Inc. trimmed its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 67.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,234 shares of the company’s stock after selling 23,500 shares during the quarter. Brave Asset Management Inc.’s holdings in CRISPR Therapeutics were worth $613,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. GSK plc bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth $168,890,000. Orbis Allan Gray Ltd lifted its holdings in CRISPR Therapeutics by 76.9% in the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after purchasing an additional 1,201,600 shares during the period. State Street Corp grew its position in CRISPR Therapeutics by 35.6% in the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after buying an additional 859,334 shares in the last quarter. ARK Investment Management LLC increased its stake in CRISPR Therapeutics by 7.5% during the 4th quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock valued at $551,777,000 after buying an additional 735,084 shares during the period. Finally, Norges Bank bought a new stake in shares of CRISPR Therapeutics during the 4th quarter worth about $25,706,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Piper Sandler reaffirmed its Buy rating, signaling continued confidence in CRISPR Therapeutics’ development pipeline and long-term commercial potential. Piper Sandler Reaffirms Their Buy Rating on CRISPR Therapeutics AG
• Positive Sentiment: Bullish commentary highlighted potential CASGEVY sales growth and expansion into in vivo gene editing through CTX310, which could broaden CRSP’s future revenue opportunities if clinical and commercial milestones are achieved. CRISPR Strong Buy CASGEVY Sales Growth and In Vivo Expansion With CTX310
• Neutral Sentiment: Brookline Capital Markets made mixed revisions: its Q3 2026 loss estimate improved slightly to $1.30 per share from $1.31, while its FY2027 loss estimate improved to $4.51 from $5.05. However, the firm still expects CRSP to remain unprofitable in 2026 and 2027.
• Negative Sentiment: Brookline reduced its Q4 2026 EPS estimate to a loss of $1.87 from $1.69 and lowered its FY2026 estimate to a loss of $5.63 from $5.36. Both forecasts are weaker than the broader current-year consensus loss estimate of $4.90, potentially weighing on sentiment.
• Negative Sentiment: The same analyst modestly cut projected profits for FY2028, FY2029 and FY2030, suggesting a slightly less optimistic view of CRSP’s long-term earnings ramp. Despite those reductions, the estimates still imply a transition from losses to profitability beginning in FY2028.

Analysts Set New Price Targets

Several research firms have recently issued reports on CRSP. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, July 8th. Wall Street Zen lowered CRISPR Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, July 5th. Citigroup boosted their price objective on CRISPR Therapeutics from $82.00 to $88.00 and gave the stock a “buy” rating in a research note on Tuesday. The Goldman Sachs Group restated a “neutral” rating and issued a $55.00 price objective on shares of CRISPR Therapeutics in a report on Thursday. Finally, Sanford C. Bernstein raised their target price on CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $68.06.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $51.64 on Friday. CRISPR Therapeutics AG has a one year low of $44.12 and a one year high of $78.48. The stock has a fifty day moving average of $52.42 and a 200-day moving average of $52.30. The company has a market capitalization of $4.99 billion, a PE ratio of -10.85 and a beta of 1.74. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.96 and a current ratio of 17.85.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. The company had revenue of $10.18 million during the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. As a group, equities analysts anticipate that CRISPR Therapeutics AG will post -4.65 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,786 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the transaction, the insider owned 19,357 shares in the company, valued at $1,076,636.34. This trade represents a 16.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by company insiders.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.